Sara Parola

Naples, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

CDK4/6i in the Underrepresented Histological Subtypes of HR±/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety.

CDK4/6i in the Underrepresented Histological Subtypes of HR±/HER2- Metastatic Breast Cancer: A Real-World Cohort Study of Effectiveness and Safety.

Journal: Clinical breast cancer
Published: April 22, 2026

The long road after breast cancer: survivorship issues and long-term treatment effects in young women.

The long road after breast cancer: survivorship issues and long-term treatment effects in young women.

Journal: Frontiers in oncology
Published: March 27, 2026

Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities.

Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities.

Journal: Exploration of targeted anti-tumor therapy
Published: April 19, 2025

PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for.

PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for.

Journal: Frontiers in genetics
Published: August 13, 2024

Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Journal: NPJ breast cancer
Published: August 02, 2024

Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Journal: NPJ breast cancer
Published: June 10, 2023

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations.

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations.

Journal: EClinicalMedicine
Published: May 22, 2023

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report.

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report.

Journal: Frontiers in oncology
Published: April 30, 2023

Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer.

Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer.

Journal: Biomolecules
Published: August 18, 2022

Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?

Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?

Journal: Cancer treatment reviews
Published: June 20, 2022

Epigenetic Regulation in Melanoma: Facts and Hopes.

Epigenetic Regulation in Melanoma: Facts and Hopes.

Journal: Cells
Published: June 26, 2021

The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?

The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?

Journal: International journal of molecular sciences
Published: May 11, 2021
Showing 1-12 of 17

Last Updated: 09/26/2026